ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

Adverse Events Of Chemo More Common Than Expected

August 25, 2006

PET Response Can Predict Increased Survival In Patients

April 27, 2012

In Brief: Heavy Smokers More Resistant To Quitting,

March 10, 1995

NIH appoints panel to review conflict of interest rules.

February 27, 2004

James Doroshow Named NCI Deputy Director, Clinical Research

June 10, 2011

NCAB Approves 8 Cancer Centers As Comprehensive

October 4, 1991